Cereplast Announces 2012 Second Quarter Financial Results
Cost of sales for the three months ended June 30, 2012 were approximately $545,000, compared to $6.7 million for the same period in 2011. Cost of sales for the first six months of 2012 totaled $1.2 million as compared to $13.2 million for the first six months of 2011. The decline in cost of sales is due to our lower variable manufacturing costs from the Company's reduced sales volumes and reduction in manufacturing overhead through lower supplies utilization and headcount attrition.
Research and development expenses for the three months ended June 30, 2012 were approximately $126,000, compared to approximately $259,000 for the same period of 2011, or a decline of over 51%. Research and development expenses for the first six months of 2012 were approximately $255,000, compared to approximately $509,000 for the first six months of 2011, or a decline of nearly 50%. The decrease was primarily due to a reduction in legal expenses and outside services used in our current product development projects.
Selling, general and administrative expenses for the three months ended June 30, 2012 were approximately $1.7 million as compared to $2.7 million for the same period in 2011. Selling, general and administrative expenses for the first six months of 2012 totaled approximately $2.9 million as compared to $4.8 million for the first six months of 2011, for a decline in both periods of over 39%. The decrease was primarily due to reduced headcount and variable sales and marketing expenses due to lower sales volume in the current year, offset by an increase in our allowance for doubtful accounts of $0.5 million in the second quarter of 2012.
Net loss for the three months ended June 30, 2012 was approximately $3.9 million as compared to $2.4 million for the same period in 2011. Net loss for the first six months of 2012 was approximately $6.7 million as compared to approximately $4.1 million for the first six months of 2011. The increase in our net loss for 2012 was primarily due to a full period of interest expense related to the coupon of our Convertible Debentures issued in May 2011, non-cash interest expense of $734,000 recognized from our Forbearance Agreement with the holders of our Convertible Debentures which reduced the conversion price in the Indenture from $5.80 to $1.00 per share, debt extinguishment costs of $427,000 related to exchange and retirement of $1 million of our Convertible Debentures and a loss of $99,000 on the change of an embedded derivative within our Warrants.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV